Suven Life Sciences has bagged two patents viz. US 7,388,024 and US 7,507,835 by US Patent Office equivalent to two New Chemical Entities for the cure of disorders related with Neurodegenerative ailments and these patents are applicable until 2024 and 2022 correspondingly.
The settled claims of the patents comprise the set of selective 5-HT compounds explored by Suven and are being grown as therapeutic specialists and are helpful in the cure of cognitive injury associated with neurodegenerative disorders.
Suven has a sum of four approved US patents of NCEs with these latest patents. These approved patents are select intellectual property of Suven and are obtained via the internal exploration research efforts.
Goods out of these inventions are likely to be out-licensed at diverse phases of clinical growth such as at phase-I or phase-II.
Suven Life Sciences is a biopharmaceutical firm aimed at developing, discovering and commercializing new pharmaceutical goods, which are first in standard or best in class therapies via the utilization of GPCR targets.